Ardea Takes the More Exciting Route

Most compounds that enter the clinical trial process never make it to market. But yesterday, Ardea Bioscicences (Nasdaq: RDEA  ) announced phase 2a data for its lead anti-HIV drug that was good enough to encourage further testing.

Ardea's lead compound, RDEA806, comes from the same class of HIV therapies (called non-nucleoside reverse transcriptase inhibitors, or NNRTIs) that have produced such hit drugs as Bristol-Myers Squibb's (NYSE: BMY  ) Sustiva and Johnson and Johnson's (NYSE: JNJ  ) recently approved Intelence.

Proving that it is possible for even a development-stage drugmaker to run a timely phase 2 clinical study (ahem), Ardea showed that RDEA806 reduced the levels of HIV in patients' bloodstreams by around 99% (2 log at the median) at one point in time in the study.

As an early peek at a drug's potential efficacy, this study comes across as positive. While it's too early to make claims regarding RDEA806's longer-term safety profile from these results, they do at least warrant further clinical testing.

RDEA806 is Ardea's lead pipeline drug candidate and all of its other compounds are still in even earlier clinical- or preclinical-stage testing, so  RDEA806's performance in testing will have a large effect on Ardea's share price.

Ardea wants to position RDEA806 as a frontline anti-HIV drug, which means it could be one of the HIV drugs of choice for newly diagnosed sufferers, if approved. Frontline HIV therapies have a relatively longer and harder development path than easier salvage-therapy drugs, intended for patients not being treated effectively with other HIV drugs.

The upshot to this strategy (although Ardea may not have had much of a choice) is that the rewards for producing a front-line HIV drug can eventually be significantly more lucrative than for developing a compound like Trimeris' (Nasdaq: TRMS  ) Fuzeon, which is used later on as HIV patients fail to improve with other drugs.

Ardea's next step with RDEA806 is for it to initiate a phase 2b study in the third quarter. This study could make or break RDEA806's future, because it will be tested head-to-head against the aforementioned Sustiva. If Sustiva significantly outperforms RDEA806 on some measures, then it will be hard to justify RDEA806's existence on the grounds of pure efficacy. Conversely, if the RDEA806 data looks good, then Ardea could have a compound worth at least a couple of hundred million dollars, considering that Sustiva sales were $956 million and grew 21% last year.

Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. See all of our latest discoveries with a 30-day free trial subscription.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. Johnson and Johnson is an active Income Investor pick. The Fool has an A+ disclosure policy.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 673539, ~/Articles/ArticleHandler.aspx, 7/24/2014 10:04:58 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 49 minutes ago Sponsored by:
DOW 17,083.80 -2.83 -0.02%
S&P 500 1,987.98 0.97 0.05%
NASD 4,472.11 -1.59 -0.04%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

6/19/2012 4:00 PM
RDEA.DL $31.96 Down +0.00 +0.00%
Ardea Biosciences,… CAPS Rating: *
BMY $49.46 Up +0.14 +0.28%
Bristol-Myers Squi… CAPS Rating: ****
GEVA $75.24 Up +2.80 +3.87%
Synageva BioPharma CAPS Rating: *
JNJ $102.20 Up +0.01 +0.01%
Johnson & Johnson CAPS Rating: ****

Advertisement